AKBA vs AMRX: Side-by-Side Comparison
Compare Akebia Therapeutics Inc (AKBA) and Amneal Pharmaceuticals Inc - Class A (AMRX) side by side: market cap USD 332.64M vs USD 5.47B. Financials, growth and model signals on Bullrun.
| Metric | AKBA | AMRX |
|---|---|---|
| Company | Akebia Therapeutics Inc | Amneal Pharmaceuticals Inc - Class A |
| Country / Exchange | United States · NASDAQ | United States · NASDAQ |
| Sector | Healthcare | Healthcare |
| Industry | Drug Manufacturers-Specialty & Generic | Drug Manufacturers-Specialty & Generic |
| Market cap | USD 332.64M | USD 5.47B |
| P/E ratio | — | 46.0 |
| Dividend yield | — | — |
| Valuation model | — | 31.0% overvalued |
| Revenue (FY2025) | USD 236.20M | USD 3.02B |
| Revenue growth YoY | +47.5% | +8.0% |
| Net income | USD -5.30M | USD 72.06M |
| Gross margin | 83.3% | 36.9% |
| Diluted EPS | -0.02 | 0.22 |